President | FACIT
David O’Neill brings extensive experience in Pharma, Biotech and seed stage investing to his role as President of FACIT. Dr. O’Neill has a wealth of networks and transaction experience through various business development roles at AstraZeneca, Ambit Biosciences (Daiichi Sankyo), Kinomescan (Discoverx/Eurofins), Fluorinov Pharma (Trillium Therapeutics). He also held operational roles including non-clinical safety, IND submission and Project Leader during clinical development of Quizartinib. He has provided interim executive management to FACIT spin outs Turnstone Biologics, Propellon and Novera Therapeutics. In addition to serving on the Board of Triphase Accelerator, he is also a Board Observer for Turnstone Biologics. Dr. O’Neill holds a PhD from Western University from the Faculty of Health Sciences with an emphasis on heat shock protein biology.
"I look at research in a different way to answer a question that really matters.”
- Dr. Reza MD (Sick Kids Nuclear Medicine, Associate Professor UofT)